A <sup>64</sup>Cu‐porphyrin‐based dual‐modal molecular probe with integrin α<sub>v</sub>β<sub>3</sub> targeting function for tumour imaging

Di Fan, Kai Wang, Hannan Gao, Qi Luo, Xin Wang, Xiaotong Li, Tong Wu, Xin Zhang, Chuangwei Luo, Guangjie Yang,

Journal of Labelled Compounds and Radiopharmaceuticals · 2020 · 17 citations · 30 references

Concepts

Abstract

Pyropheophorbide‐a (Pyro) is a promising multifunctional molecule for multimodal tumour imaging and photodynamic therapy, but its clinical applications are seriously restricted by the limited tumour accumulation capability. Here, we designed and synthesized a small‐molecule probe that achieved specific dual‐modal tumour imaging based on Pyro. Briefly, a novel molecule combining Pyro, an RGD dimer peptide (3PRGD 2 ) and 64 Cu, was designed and synthesized, and the obtained molecule, 64 Cu‐Pyro‐3PRGD 2 , exhibited high tumour specificity in both positron emission tomography and optical imaging in vivo. c (RGDfk) peptide blocking significantly reduced the efficacy of the probe, which confirmed the integrin α V β 3 targeting of this molecular probe. 64 Cu‐Pyro‐3PRGD 2 had very low accumulation in normal organs and could be rapidly cleared through kidney metabolism, which prevented the potential damage to adjacent normal tissues. Overall, combining tumour targeting, dual‐modal imaging, and biosafety, 64 Cu‐Pyro‐3PRGD 2 has the potential for clinical use as a molecular imaging probe for tumour diagnosis.

References

30